Clinical Trials Logo
  1. Home
  2. Peripheral Arterial Disease
  3. NCT05084066

A Study on the Phenomenon of Remote Ischaemic Preconditioning in Patients With Peripheral Artery Disease

Peripheral Arterial Disease Clinical Trial

Official title:
A Study on the Phenomenon of Remote Ischaemic Preconditioning in Patients With Peripheral Artery Disease

Clinical Trial Summary

This study aims to evaluate whether remote ischemic preconditioning (RIPC) daily for 28 days reduces the symptoms of intermittent claudication in patients with peripheral artery disease (PAD). The study evaluates the effect of RIPC on patients' total walking distance (TWC), initial claudication distance (ICD), and time to relief of claudication (TRC). In addition, the trial investigates the effect of RIPC on different arterial functional characteristics and low molecular weight metabolites in serum and affected skeletal muscle.

Clinical Trial Description

A research hypothesis is that repeated remote ischemic preconditioning (RIPC) daily for 28 days reduces the symptoms of intermittent claudication in patients with peripheral artery disease (PAD). The investigators plan to conduct a randomized controlled trial. Clinically stable patients with PAD and intermittent claudication are randomly allocated to receive a repeated RIPC or sham for 28 days. An automated device generates RIPC. One cycle of RIPC consists of 4 cycles of 5-min upper limb ischemia followed by 5-min reperfusion (lasting a total of 35 minutes). The participant places the device on his upper arm and presses the "Start "button, starting the intervention. The intervention occurs at rest in the participant's home environment. The first intervention takes place in the research center, where the research assistant teaches the participant how to use the device. In the sham group, a RIPC imitation is performed. The sham device has the same sound and light effects as the active device; the only difference is that the pressure in the cuff does not increase, so ischemia does not occur. Randomization is performed using blocks. Each block has 2-4 subjects. Subjects are divided according to smoking status (active smoker yes/no) and age (≥ 65 years or < 65 years old). Randomized letters (whether the subject will go into the experimental group or the sham group) are placed in opaque envelopes, which are opened right before the first intervention. Participants will visit the research center twice. During the first visit, they fill in the VASCUQOL-6 questionnaire to evaluate their symptoms and health-related quality of life. In addition, the investigators collect participants' blood and urine samples, measure their arterial stiffness parameters and assess symptom-free and maximal walking distance on a treadmill. The investigators will take a skeletal muscle biopsy from the first ten participants in each group using a tiny percutaneous needle biopsy (TPNB) technique to measure low molecular weight metabolites in affected skeletal muscle. These steps are repeated on the second visit (after 28 days of intervention). After data collection is completed, a statistical analysis is performed to evaluate whether RIPC improves participants' maximal walking distance, arterial stiffness, and metabolic parameters. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05084066
Study type Interventional
Source Tartu University Hospital
Contact
Status Completed
Phase N/A
Start date January 24, 2022
Completion date April 18, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1